Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Co-existent Endometrial And Fallopian Tube Carcinoma, Molecular And Pathological Features For Risk Stratification.
  1. Home
  3. Co-existent Endometrial And Fallopian Tube Carcinoma, Molecular And Pathological Features For Risk Stratification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Current oncology (Toronto, Ont.)·2026
Same author

Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Vulvar Squamous Cell Carcinoma: Scientific Progress and Impacts to Pathology Practice.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
Same author

Assessing the essential parameters of race, ethnicity and geography in endometrial cancer and the impact on presentation, treatment and outcomes.

Gynecologic oncology·2026
Same author

Recommendations for Pathologist-Led Deployment of Artificial Intelligence Tools as Laboratory-Developed Tests.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Coexistent Endometrial and Ovarian Carcinoma: Terminology, Clinicopathological Features, and Clinical Significance.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
Same journal

Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption and Dismal Prognosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

RUNX2 Rearrangement as a Recurrent Molecular Event and Diagnostic Marker in Salivary Gland Keratocystoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Clinicopathological, Molecular and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Baseline Tumor Proliferation and Ki-67 Are Associated With Pathologic Response to Neoadjuvant Chemoimmunotherapy in NSCLC.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Pulmonary Neuroendocrine Tumor Artificial Intelligence-Assisted Prediction of Postoperative Recurrence from Tumor Biopsy Specimens.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Amplification and Overexpression of Cyclin D1 in Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Targeted Next-Generation Sequencing Study.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
See all related articles

Related Experiment Video

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

Co-Existent Endometrial and Fallopian Tube Carcinoma, Molecular and Pathological Features for Risk Stratification.

Kianoosh Keyhanian1, C Blake Gilks2, Elizabath Priya Mathew1

  • 1Department of Pathology of Laboratory Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|June 19, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

This study adapted FIGO 2023 criteria for co-existent endometrial and fallopian tube carcinoma, identifying a low-risk group with no recurrences. Refining criteria with molecular features may expand this low-risk category for potential treatment de-escalation.

Keywords:
Endometrial carcinomaco-existent endometrial and ovarian carcinomafallopian tube carcinomamolecular classification

More Related Videos

An Efficient Method for Extracting Human Fallopian Tube Epithelia for Single-cell Analyses
07:03

An Efficient Method for Extracting Human Fallopian Tube Epithelia for Single-cell Analyses

Published on: March 28, 2025

Related Experiment Videos

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

An Efficient Method for Extracting Human Fallopian Tube Epithelia for Single-cell Analyses
07:03

An Efficient Method for Extracting Human Fallopian Tube Epithelia for Single-cell Analyses

Published on: March 28, 2025

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Molecular Diagnostics

Background:

  • Co-existent endometrial and ovarian carcinoma (CEOC) meeting FIGO 2023 IA3 criteria have an excellent prognosis.
  • Excluding high-risk molecular subtypes (MMRd, p53abn, NSMP ER-low/negative) improves risk stratification in CEOC.
  • Co-existent endometrial carcinoma (EC) with fallopian tube (FT) involvement is classified as advanced stage (pT3/FIGO III).

Purpose of the Study:

  • To evaluate if FIGO 2023 IA3 criteria can identify low-risk patients with co-existent endometrial and FT carcinoma.
  • To determine if molecular features can further refine prognostic stratification in this patient group.
  • To explore potential treatment de-escalation strategies for identified low-risk patients.

Main Methods:

  • Retrospective analysis of 71 patients with pT3a EC and FT involvement from two institutions.
  • Exclusion of cases with nodal, pelvic, vaginal, parametrial, adnexal soft tissue, peritoneal involvement, or neoadjuvant therapy.
  • Application of FIGO 2023 IA3 criteria and molecular profiling (MMRd, p53abn, NSMP ER-low/negative) for risk assessment.

Main Results:

  • Eight patients (11.3%) met the adapted FIGO 2023 IA3 criteria with zero recurrences.
  • A modified approach excluding adverse molecular features and including ovarian/bilateral adnexal involvement identified 11 patients (15.5%) with no recurrences.
  • Recurrences (19.7%) were predominantly associated with high-grade endometrioid or non-endometrioid histotypes and adverse molecular features.

Conclusions:

  • Adapted FIGO 2023 IA3 criteria can identify a subset of patients with co-existent endometrial and FT carcinoma at low risk of recurrence.
  • Incorporating molecular features and expanding pathological criteria can potentially identify a larger low-risk group.
  • These findings support considering treatment de-escalation for selected patients with uterus/adnexa-confined carcinoma and indolent disease behavior.